SOUTH SAN FRANCISCO, Calif. — August 28, 2025 — Leads & Copy — CytomX Therapeutics, Inc. (Nasdaq: CTMX) will participate in investor conferences in September, including the Cantor Global Healthcare Conference 2025 on Sept. 4 in New York, NY, the H.C. Wainwright 27th Annual Global Investment Conference on Sept. 9 in New York, NY and the Morgan Stanley 23rd Annual Global Healthcare Conference on Sept. 10 in New York, NY. A live webcast will be available on the Events and Presentations page of CytomX’s website. Management will be available for one-on-one meetings with registered investors.
CytomX is a clinical-stage, oncology-focused biopharmaceutical company developing novel conditionally activated, masked biologics designed to localize to the tumor microenvironment. Its PROBODY® therapeutic platform aims to create safer, more effective cancer therapies. The technology platform has produced therapeutic candidates across modalities, including antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators such as cytokines. Clinical-stage pipeline includes CX-2051 and CX-801. CytomX has collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron and Moderna.
Company Contact:
Chris Ogden
SVP, Chief Financial Officer
cogden@cytomx.com
Investor Contact:
Precision AQ (formerly Stern Investor Relations)
Stephanie Ascher
stephanie.ascher@precisionaq.com
Media Contact:
Redhouse Communications
Teri Dahlman
teri@redhousecomms.com
Source: CytomX Therapeutics, Inc.
